ClinicalTrials.gg

Program

ensartinib

Also written as “Ensartinib”, “Phase I: X-396 (ensartinib)” and “Phase II: X-396 (ensartinib)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Lung Neoplasms, led by Betta Pharmaceuticals.

Furthest: phase 3, since Apr 30, 201612 company-led studies, 5 open or runningNext primary completion: Feb 1, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Betta Pharmaceuticals125 open or runningphase 3since Apr 30, 2016Jun 15, 2012Feb 1, 2029phase 2 · NCT07448116

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 15, 2012First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT01625234 · 131 enrolled · United States
  2. Apr 30, 2016Phase 3 study in Carcinoma, Non-Small-Cell LungNCT02767804 · 290 enrolled · United States, Argentina, Australia and more
  3. Nov 6, 2016Phase 1 study in Solid TumorNCT02959619 · 48 enrolled · China
  4. Jul 11, 2017Phase 2 study in Carcinoma, Non-Small-Cell LungNCT03215693 · 152 enrolled · China
  5. Apr 15, 2018Phase 1 study in Lung NeoplasmsNCT03536481 · 74 enrolled · China
  6. May 16, 2018Phase 2 study in Lung NeoplasmsNCT03608007 · 69 enrolled · China
  7. Dec 26, 2018Phase 1 study in ALK-POSITIVE NSCLCNCT03804541 · 6 enrolled · China
  8. May 29, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04415320 · 37 enrolled · China
  9. Apr 18, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05341583 · 202 planned · China
  10. Oct 21, 2022Phase 1 study in BioequivalencyNCT05665283 · 32 enrolled · United States
  11. Jul 1, 2024Phase 1 study in HealthyNCT06492525 · 36 planned · China
  12. Jan 31, 2026Phase 2 study in Solid Advanced TumorNCT07448116 · 164 planned · China

Ahead

  1. Feb 1, 2029Primary completion: phase 2 study in Solid Advanced TumorNCT07448116

TargetBeta

ALK →read by rule
“An orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), ”NCIt, by rule
“ALK tyrosine kinase receptor inhibitor”ChEMBL 37, by rule

Other programs on ALK

ProgramCompanyFurthest phaseStudies
CrizotinibrulePfizerphase 431
lorlatinibrulePfizerphase 420
gilteritinibruleAstellas Pharmaphase 320
repotrectinibruleBristol-Myers Squibbphase 39
neladalkibGlaxoSmithKlinephase 32
Foritinib SuccinateFosun Pharmaphase 21
ALK Molecular Glue Degrader TRI-611ruletriana-biomedicines-incphase 21
AQUA07Hoffmann-La Rochephase 11
SIM0518ruleSimcere Pharmaceutical Groupphase 11

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07448116Solid Advanced Tumor · China2RecruitingFeb 1, 2029164
NCT06492525Healthy · China1Not yet recruitingOct 202436
NCT05665283Bioequivalency · United States1CompletedJan 18, 202332
NCT05341583Carcinoma, Non-Small-Cell Lung · China3RecruitingJun 1, 2025202
NCT04415320Carcinoma, Non-Small-Cell Lung · China2UNKNOWNDec 202037
NCT03804541ALK-POSITIVE NSCLC · China1UNKNOWNJun 20196
NCT03608007Lung Neoplasms · China2UNKNOWNMar 202069
NCT03536481Lung Neoplasms · China1CompletedJan 9, 201974
NCT03215693Carcinoma, Non-Small-Cell Lung · China2Active, not recruitingMar 9, 2020152
NCT02959619Solid Tumor · China1CompletedOct 31, 201948
NCT02767804Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingDec 30, 2025290
NCT01625234Carcinoma, Non-Small-Cell Lung · United States2CompletedSep 17, 2020131

How it is read

Names in the registry

  • “Ensartinib”, 6 entries
  • “Phase I: X-396 (ensartinib)”, 1 entry
  • “Phase II: X-396 (ensartinib)”, 1 entry
  • “X-396 (ensartinib)”, 1 entry
  • “Ensartinib Hydrochloride”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.